CMS
ABBV icon

Capital Market Strategies’s AbbVie ABBV Stock Holding History

Capital Market Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.44M Sell
7,757
-1,975
-20% -$367K 1% 17
2025
Q1 		$2.04M Sell
9,732
-947
-9% -$184K 1.36% 15
2024
Q4 		$1.9M Buy
10,679
+89
+0.8% +$16.4K 1.09% 18
2024
Q3 		$2.09M Sell
10,590
-91
-0.9% -$17K 1.26% 14
2024
Q2 		$1.83M Buy
10,681
+305
+3% +$50.5K 1.16% 16
2024
Q1 		$1.89M Sell
10,376
-528
-5% -$91K 1.44% 13
2023
Q4 		$1.69M Sell
10,904
-689
-6% -$100K 1.47% 11
2023
Q3 		$1.71M Sell
11,593
-303
-3% -$44.5K 1.7% 9
2023
Q2 		$1.6M Sell
11,896
-131
-1% -$19.2K 1.48% 11
2023
Q1 		$1.92M Buy
12,027
+575
+5% +$87.9K 3.4% 8
2022
Q4 		$1.85M Sell
11,452
-29
-0.3% -$4.45K 1.99% 11
2022
Q3 		$1.54M Buy
11,481
+61
+0.5% +$8.75K 1.73% 11
2022
Q2 		$1.75M Buy
11,420
+532
+5% +$81.3K 1.84% 9
2022
Q1 		$1.76M Sell
10,888
-268
-2% -$38.9K 1.53% 11
2021
Q4 		$1.51M Buy
+11,156
New +$1.32M 1.24% 17

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Capital Market Strategies's ABBV Position: Q2 2025 in Review

Capital Market Strategies reduced its AbbVie (ABBV) stake by 20% in Q2 2025, selling an estimated $367K and leaving 7,757 shares worth $1.44M. The position accounts for 1% of the portfolio, ranked #17.

Capital Market Strategies first reported a position in ABBV in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.09M in Q3 2024. 3,787 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Capital Market Strategies held 7,757 shares of AbbVie worth $1.44M as of Q2 2025.
  • Capital Market Strategies sold 1,975 AbbVie shares in Q2 2025, an estimated $367K.
  • AbbVie made up 1% of Capital Market Strategies's portfolio in Q2 2025, its #17 holding.
  • Capital Market Strategies first reported a position in AbbVie in Q4 2021 and has held it in 15 quarters since.
  • Capital Market Strategies's AbbVie position peaked at $2.09M in Q3 2024.
  • 3,787 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Capital Market Strategies's 13F filing for Q2 2025, filed 2 Jul 2025.